JP2023550672A5 - - Google Patents
Info
- Publication number
- JP2023550672A5 JP2023550672A5 JP2022576508A JP2022576508A JP2023550672A5 JP 2023550672 A5 JP2023550672 A5 JP 2023550672A5 JP 2022576508 A JP2022576508 A JP 2022576508A JP 2022576508 A JP2022576508 A JP 2022576508A JP 2023550672 A5 JP2023550672 A5 JP 2023550672A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- approximately
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038433P | 2020-06-12 | 2020-06-12 | |
| US63/038,433 | 2020-06-12 | ||
| PCT/US2021/036923 WO2021252835A1 (en) | 2020-06-12 | 2021-06-11 | Dosing of polyomavirus neutralizing antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023550672A JP2023550672A (ja) | 2023-12-05 |
| JP2023550672A5 true JP2023550672A5 (https=) | 2024-06-18 |
Family
ID=78846596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022576508A Pending JP2023550672A (ja) | 2020-06-12 | 2021-06-11 | ポリオーマウイルス中和抗体の投薬 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230220051A1 (https=) |
| EP (1) | EP4165078A4 (https=) |
| JP (1) | JP2023550672A (https=) |
| KR (1) | KR20230029781A (https=) |
| CN (1) | CN116096746A (https=) |
| AU (1) | AU2021288699A1 (https=) |
| BR (1) | BR112022025020A2 (https=) |
| CA (1) | CA3186736A1 (https=) |
| IL (1) | IL298956A (https=) |
| MX (1) | MX2022015740A (https=) |
| TW (1) | TW202207986A (https=) |
| WO (1) | WO2021252835A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016105572A1 (en) * | 2014-12-24 | 2016-06-30 | Millennium Pharmaceuticals, Inc. | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
| US9862760B2 (en) * | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
-
2021
- 2021-06-11 BR BR112022025020A patent/BR112022025020A2/pt unknown
- 2021-06-11 CA CA3186736A patent/CA3186736A1/en active Pending
- 2021-06-11 AU AU2021288699A patent/AU2021288699A1/en active Pending
- 2021-06-11 CN CN202180056557.5A patent/CN116096746A/zh active Pending
- 2021-06-11 MX MX2022015740A patent/MX2022015740A/es unknown
- 2021-06-11 TW TW110121461A patent/TW202207986A/zh unknown
- 2021-06-11 KR KR1020237001273A patent/KR20230029781A/ko active Pending
- 2021-06-11 JP JP2022576508A patent/JP2023550672A/ja active Pending
- 2021-06-11 IL IL298956A patent/IL298956A/en unknown
- 2021-06-11 EP EP21822254.5A patent/EP4165078A4/en active Pending
- 2021-06-11 WO PCT/US2021/036923 patent/WO2021252835A1/en not_active Ceased
-
2022
- 2022-12-09 US US18/064,081 patent/US20230220051A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022002524A5 (https=) | ||
| EA016626B1 (ru) | Способ лечения натализумабом воспалительного и/или аутоиммунного заболевания (варианты) | |
| TW202031287A (zh) | 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法 | |
| JP2020536097A5 (https=) | ||
| WO2017064615A1 (en) | Use of c5 inhibitors in transplant associated microangiopathy | |
| JP2023528441A5 (https=) | ||
| JP2022525164A5 (https=) | ||
| JP2021525718A5 (https=) | ||
| US20220340668A1 (en) | Treatment of liver disease or disorder comprising actrii receptor antagonists | |
| TW201439118A (zh) | Ｂｍｐ－６抗體 | |
| AU2022200690B2 (en) | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists | |
| AU2021309957A1 (en) | Anti-IL-36R antibodies for the treatment of neutrophilic dermatoses | |
| JP2023550672A5 (https=) | ||
| JP2024540435A5 (https=) | ||
| TW202235435A (zh) | 抗cd38抗體及其用途 | |
| CN116178530A (zh) | 抗体在治疗SARS-CoV-2感染的用途 | |
| US20220112294A1 (en) | Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies | |
| US20230009657A1 (en) | Methods of treating lupus nephritis using interleukin-17 (il-17) antagonists | |
| US20240175027A1 (en) | Anti-c5 antibody/c5 irna co-formulations and combination therapies | |
| CA3257386A1 (en) | METHOD FOR TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | |
| CA3216063A1 (en) | Treatment for lupus nephritis using anti-baffr antibodies | |
| EP4334351A1 (en) | Treatment for systemic lupus erythematosus using anti-baffr antibodies | |
| AU2024349732A1 (en) | Methods for the treatment of cardiovascular disease | |
| EA051888B1 (ru) | Антитела против il-36r для лечения нейтрофильных дерматозов | |
| HK40099176A (zh) | 抗cd38抗体及其用途 |